These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 15828906

  • 1. Efficacy of percutaneous ethanol injection therapy for secondary hyperparathyroidism in patients on hemodialysis as evaluated by parathyroid hormone levels according to K/DOQI guidelines.
    Tanaka M, Itoh K, Matsushita K, Matsushita K, Fukagawa M.
    Ther Apher Dial; 2005 Feb; 9(1):48-52. PubMed ID: 15828906
    [Abstract] [Full Text] [Related]

  • 2. Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism.
    Tanaka M, Itoh K, Matsushita K, Matsushita K, Fukagawa M.
    Nephron Clin Pract; 2006 Feb; 102(1):c1-7. PubMed ID: 16166800
    [Abstract] [Full Text] [Related]

  • 3. Parathyroid interventions for secondary hyperparathyroidism in hemodialyzed patients.
    Onoda N, Kashiwagi T, Nakamura T, Niitsu Y, Omata M, Kurihara S.
    Ther Apher Dial; 2005 Aug; 9 Suppl 1():S11-5. PubMed ID: 16109135
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of percutaneous ethanol injection therapy (PEIT) is related to the number of parathyroid glands in haemodialysis patients with secondary hyperparathyroidism.
    Koiwa F, Kakuta T, Tanaka R, Yumita S.
    Nephrol Dial Transplant; 2007 Feb; 22(2):522-8. PubMed ID: 17127701
    [Abstract] [Full Text] [Related]

  • 5. Long-term (3 years) prognosis of parathyroid function in chronic dialysis patients after percutaneous ethanol injection therapy guided by colour Doppler ultrasonography.
    Tanaka R, Kakuta T, Fujisaki T, Tanaka S, Sakai H, Kurokawa K, Saito A.
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii58-61. PubMed ID: 12771303
    [Abstract] [Full Text] [Related]

  • 6. [A case of secondary hyperparathyroidism with an ectopic intrathyroid gland successfully diagnosed and controlled by percutaneous ethanol injection therapy (PEIT)].
    Tanaka M, Itoh K, Matsushita K, Ogawa A, Hirayama H, Tsunoda N, Yoshizumi K, Naruse M, Nonoguchi H, Tomita K.
    Nihon Jinzo Gakkai Shi; 2002 May; 44(4):409-13. PubMed ID: 12073627
    [Abstract] [Full Text] [Related]

  • 7. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients.
    Kakuta T, Fukagawa M, Fujisaki T, Hida M, Suzuki H, Sakai H, Kurokawa K, Saito A.
    Am J Kidney Dis; 1999 Jun; 33(6):1091-9. PubMed ID: 10352197
    [Abstract] [Full Text] [Related]

  • 8. Long-term prognosis of parathyroid function after successful percutaneous ethanol injection therapy (PEIT) guided by color Doppler flow mapping in chronic dialysis patients.
    Kakuta T, Kunimatsu K, Tadaki F, Fujisaki T, Noguchi M, Abe Y, Sakai H, Kurokawa K, Saito A.
    Biomed Pharmacother; 2000 Jun; 54 Suppl 1():60s-65s. PubMed ID: 10914993
    [Abstract] [Full Text] [Related]

  • 9. Clinical experience with percutaneous ethanol injection therapy in hemodialysis patients with renal hyperparathyroidism.
    Nakamura M, Fuchinoue S, Teraoka S.
    Am J Kidney Dis; 2003 Oct; 42(4):739-45. PubMed ID: 14520624
    [Abstract] [Full Text] [Related]

  • 10. Ultrasound in clinical setting of secondary hyperparathyroidism.
    Meola M, Petrucci I, Cupisti A.
    J Nephrol; 2013 Oct; 26(5):848-55. PubMed ID: 23042437
    [Abstract] [Full Text] [Related]

  • 11. [PEIT is the part of strategy for severe hyperparathyroidism in patients requiring hemodialysis].
    Uemura K, Kakuta T.
    Clin Calcium; 2004 Sep; 14(9):88-92. PubMed ID: 15577118
    [Abstract] [Full Text] [Related]

  • 12. Time course of change in calcium x phosphorus product after percutaneous ethanol injection therapy.
    Koiwa F, Hasegawa T, Kojima I, Ideura T.
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii53-7. PubMed ID: 12771302
    [Abstract] [Full Text] [Related]

  • 13. Treatment of refractory secondary hyperparathyroidism with ethanol injection: the importance of glandular volume.
    Douthat WG, Orozco SE, de Arteaga J, Massari PU.
    Kidney Int Suppl; 2003 Jun; (85):S101-4. PubMed ID: 12753277
    [Abstract] [Full Text] [Related]

  • 14. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H, Sato T, Kurihara T, Kurosawa T, Fukagawa M.
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [Abstract] [Full Text] [Related]

  • 15. [Percutaneous ethanol injections in the treatment of secondary hyperparathyroidism].
    Kuzdak K, Rybińska A, Białas M.
    Endokrynol Pol; 2005 Feb; 56(6):891-6. PubMed ID: 16821207
    [Abstract] [Full Text] [Related]

  • 16. Renoprotection following treatment of secondary hyperparathyroidism with percutaneous ethanol injection in pre-dialysis patients.
    Chen HH, Chen YC, Yeh JC.
    Nephron; 2002 Sep; 92(1):105-10. PubMed ID: 12187092
    [Abstract] [Full Text] [Related]

  • 17. Magnetic resonance imaging (MRI) and technetium-99m-methoxyisonitrile (MIBI) scintigraphy to evaluate the abnormal parathyroid gland and PEIT efficacy for secondary hyperparathyroidism.
    Wada A, Sugihara M, Sugimura K, Kuroda H.
    Radiat Med; 1999 Sep; 17(4):275-82. PubMed ID: 10510900
    [Abstract] [Full Text] [Related]

  • 18. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU.
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [Abstract] [Full Text] [Related]

  • 19. Surgical indications and procedures of parathyroidectomy in patients with chronic kidney disease.
    Tominaga Y, Matsuoka S, Sato T.
    Ther Apher Dial; 2005 Feb; 9(1):44-7. PubMed ID: 15828905
    [Abstract] [Full Text] [Related]

  • 20. Role of the parathyroid gland vascularization index in predicting percutaneous ethanol injection efficacy in refractory uremic hyperparathyroidism.
    Chen HH, Lu KC, Lin CJ, Wu CJ.
    Nephron Clin Pract; 2011 Feb; 117(2):c120-6. PubMed ID: 20693813
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.